Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 20, 2025 07:30 ET | Source: Altimmune, Inc

Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025

Oral presentation to highlight 24-week efficacy and safety data Poster to feature results of AI-based analyses of liver fibrosis reduction GAITHERSBURG, Md., Oct. 20, 2025 (GLOBE NEWSWIRE) --...
October 15, 2025 12:24 ET | Source: Art Palm Beach

Art Palm Beach 2026 Ignites the Season with Global Galleries and Bold New Voices

Art Palm Beach returns for their 4th annual Modern & Contemporary show
October 15, 2025 08:00 ET | Source: Monopar Therapeutics Inc.

Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025

WILMETTE, Ill., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments...
October 10, 2025 08:00 ET | Source: AskBio Inc. (AskBio)

AskBio Presents Interim Safety Results from Phase 1/Phase 2 LION-CS101 Clinical Trial of AB-1003 in Participants with Limb-Girdle Muscular Dystrophy 2I/R9

Research Triangle Park, N.C., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Data from first cohort of five participants suggest an acceptable safety profile for AB-1003 in participants with limb-girdle...
October 08, 2025 14:06 ET | Source: Ölgerðin Egill Skallagrimsson

Ölgerðin Egill Skallagrímsson hf.: Upplýsingar um birtingu uppgjörs fyrir tímabilið 1. mars 2025 - 31. ágúst 2025

Ölgerðin Egill Skallagrímsson hf. mun birta árshlutauppgjör félagsins fyrir tímabilið 1. mars 2025 til 31. ágúst 2025, eftir lokun markaða fimmtudaginn 9. október 2025. Kynningarfundur vegna...
October 07, 2025 08:30 ET | Source: Aligos Therapeutics

Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025

SOUTH SAN FRANCISCO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through...
October 07, 2025 08:00 ET | Source: Bluejay Therapeutics

Bluejay Therapeutics Announces Data Presentations in Chronic Hepatitis D (CHD) and Chronic Hepatitis B (CHB) at Upcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025

REDWOOD CITY, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing potentially life-changing therapeutics for...
October 07, 2025 08:00 ET | Source: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025

BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral...
October 07, 2025 08:00 ET | Source: Arbutus Biopharma Corporation

Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025

Multiple abstracts accepted featuring imdusiran clinical data – highlighting progress toward a potential functional cure for chronic hepatitis B virus AB-101 clinical data abstract recognized as a...
October 07, 2025 08:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics to Present at the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2025

NORCROSS, Ga., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal...